According to data from the registry, it is estimated that roughly 75% of PNH patients receive eculizumab therapy [5] with pegcetacoplan introduced in 2021 as the first proximal complement inhibitor (C3-inhibition/ pegylated cyclic tridecapeptide) [4,6]. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.